Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

H.I. Andtbacka, Robert; L. Kaufman, Howard; A. Collichio, Frances; Amatruda, Thomas; Senzer, Neil; Chesney, Jason; A. Delman, Keith; E. S̄pitler, Lynn; Puzanov, Igor; S. Agarwala, Sanjiv; Milhem, Mohammed; D. Cranmer, Lee; D. Curti, Brendan; D. Lewis, Karl; I. Ross, Merrick; H. Guthrie, Troy; P. Linette, Gerald; A. Daniels, Gregory; J. Harrington, Kevin; R. Middleton, Mark; H. Miller, Wilson; S. Zager, Jonathan; Ye, Yining; Yao, Bin; Ai, Li; Doleman, Susan; M. Vanderwalde, Ari; Gansert, Jennifer; S. Coffin, Robert

doi:10.1200/jco.2014.58.3377

Public

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Published in Journal of Clinical Oncology • May 27, 2015

Authors:

Robert H.I. Andtbacka

Howard L. Kaufman

Frances A. Collichio

Abstract

PURPOSE: Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic antitumor immune responses. T-VEC was compared with GM-...

Subject

Medicine

Oncolytic virus

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!